Glaxo receives FDA 'complete response' for cervical cancer vaccine


2007-12-17 08:24

GlaxoSmithKline (NYSE: GSK) announced today that it has received a complete response letter from the U.S. Food and Drug Administration related to its application for the cervical cancer vaccine, CERVARIX

Advertisement

Reporter and Bloggers, Write for EmaxHealth and Get Paid. Click to Contact Us For Details

Share this content.